Quarterly ResultMay 12, 2026, 04:17 PM
AnaptysBio Completes Spin-off; Q1 Net Loss $52.9M
AI Summary
AnaptysBio, Inc. completed the spin-off of First Tracks Biotherapeutics, Inc. in late April 2026, now exclusively managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. The company reported a Q1 2026 net loss of $52.9 million, or $1.84 per share, on collaboration revenue of $25.6 million. AnaptysBio also announced the appointment of Chris Murphy as CFO and Susannah Gray and Owen Hughes to its Board of Directors, alongside a $100.0 million stock repurchase plan.
Key Highlights
- Completed spin-off of First Tracks Biotherapeutics in late April 2026.
- Q1 2026 net loss was $52.9 million, or $1.84 per share.
- Q1 2026 collaboration revenue was $25.6 million, down from $27.8 million YoY.
- Jemperli royalties increased 44% to $24.7 million in Q1 2026.
- Announced a $100.0 million Stock Repurchase Plan in March 2026.
- Cash, cash equivalents, and investments totaled $286.5 million as of March 31, 2026.
- GSK Jemperli Q1 2026 sales were $313 million, with >40% year-over-year growth.
- Appointed Chris Murphy as CFO and Susannah Gray and Owen Hughes to the Board of Directors.